https://www.tbnet.eu/tbnet-publications/tuberculosis-incidence-in-solid-organ-transplant-recipients-in-europe%3A-a-multicenter-tbnet-cohort-study.- 2026-01-20 https://www.tbnet.eu/tbnet-publications/diagnostic-accuracy-and-predictive-value-of-the-quantiferon-tb-gold-plus-assay-for-tuberculosis-in-immunocompromised-individuals%3A-a-prospective-tbnet-study 2025-08-20 https://www.tbnet.eu/tbnet-publications/treatment-outcomes-of-extensively-drug-resistant-tuberculosis-in-europe%3A-a-retrospective-cohort-study 2025-08-20 https://www.tbnet.eu/tbnet-publications/urgent-request-for-pretomanid-label-expansion-to-align-with-who-guidelines-and-improve-treatment-accessibility-and-efficacy 2025-08-20 https://www.tbnet.eu/tbnet-publications/a-year-in-review-on-tuberculosis-and-non--tuberculous-mycobacteria-disease%3A-a-2025-update-for-clinicians-and-scientists 2025-03-21 https://www.tbnet.eu/tbnet-publications/tuberculosis-in-adult-migrants-in-europe%3A-a-tbnet-consensus-statement 2025-03-21 https://www.tbnet.eu/tbnet-publications/use-of-putative-hepatoprotective-agents-as-an-adjunct-to-anti-tb-treatment-in-europe 2025-03-21 https://www.tbnet.eu/tbnet-publications/screening-of-refugees-from-ukraine-for-tb%3A-a-tbnet-survey 2025-03-21 https://www.tbnet.eu/tbnet-publications/availability-of-drugs-and-resistance-testing-for-bpalm-regimen-for-rifampicin-resistant-tuberculosis-in-europe 2025-03-21 https://www.tbnet.eu/tbnet-publications/tuberculosis-disease-in-immunocompromised-children-and-adolescents%3A-a-ptbnet-multi-centre-case-control-study 2025-03-21 https://www.tbnet.eu/tbnet-publications/tuberculosis-screening-in-migrants-to-the-eu%2Feea-and-uk 2025-03-21 https://www.tbnet.eu/tbnet-publications/tuberculosis-in-foreign-born-persons-in-europe 2025-03-21 https://www.tbnet.eu/tbnet-publications/performance-of-quantiferon-tb-gold-plus-assays-in-paediatric-tuberculosis%3A-a-multicentre-ptbnet-study 2025-03-21 https://www.tbnet.eu/tbnet-publications/relative-cost-of-multidrug-resistant-tuberculosis-medicines-in-europe. 2025-03-21 https://www.tbnet.eu/tbnet-publications/predictive-performance-of-interferon-gamma-release-assays-and-the-tuberculin-skin-test-for-incident-tuberculosis%3A-an-individual-participant-data-meta-analysis.- 2025-03-21 https://www.tbnet.eu/tbnet-publications/clinical-implications-of-molecular-drug-resistance-testing-for-mycobacterium-tuberculosis%3A-a-2023-tbnet%2Fresist-tb-consensus-statement. 2025-03-21 https://www.tbnet.eu/tbnet-publications/availability-and-costs-of-medicines-for-the-treatment-of-tuberculosis-in-europe.- 2025-03-21 https://www.tbnet.eu/tbnet-publications/relative-cost-of-multidrug-resistant-tuberculosis-medicines-in-europe.- 2023-06-18 https://www.tbnet.eu/tbnet-publications/clinical-implications-of-molecular-drug-resistance-testing-for-mycobacterium-tuberculosis%3A-a-2023-tbnet%2Fresist-tb-consensus-statement.- 2023-06-18 https://www.tbnet.eu/tbnet-publications/availability-and-costs-of-medicines-for-the-treatment-of-tuberculosis-in-europe. 2023-06-18 https://www.tbnet.eu/tbnet-publications/rifapentine-access-in-europe%3A-growing-concerns-over-key-tuberculosis-treatment-component.- 2025-03-21 https://www.tbnet.eu/tbnet-publications/co-administration-of-treatment-for-rifampicin-resistant-tb-and-chronic-hcv-infection%3A-a-tbnet-and-esgmyc-study. 2022-07-09 https://www.tbnet.eu/tbnet-publications/safety-and-outcomes-of-amikacin-liposome-inhalation-suspension-for-mycobacterium-abscessus-pulmonary-disease%3A-a-ntm-net. 2022-07-09 https://www.tbnet.eu/tbnet-publications/meningitis-study-group.-treatment-and-outcome-in-children-with-tuberculous-meningitis---a-multi-centre-paediatric-tuberculosis-network-european-trials-group-study 2022-07-09 https://www.tbnet.eu/tbnet-publications/the-ability-of-the-neonatal-immune-response-to-handle-sars-cov-2-infection.- 2022-07-09 https://www.tbnet.eu/tbnet-publications/discovery-and-validation-of-a-personalized-risk-predictor-for-incident-tuberculosis-in-low-transmission-settings. 2022-07-09 https://www.tbnet.eu/tbnet-publications/epidemiology-of-nontuberculous-mycobacterial-pulmonary-disease-in-europe-and-japan-by-delphi-estimation.- 2022-07-09 https://www.tbnet.eu/tbnet-publications/management-of-drug-toxicity-in-m.-avium-complex-pulmonary-disease---an-expert-panel-survey.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/non-tuberculous-mycobacterial-lung-disease-in-patients-with-bronchiectasis%3A--perceived-risk%2C-severity-and-guideline-adherence-in-a-european-physician-survey. 2021-02-07 https://www.tbnet.eu/tbnet-publications/covid-19-in-children-and-adolescents-in-europe%3A-a-multinational%2C-multicentre-cohort-study.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/multidrug-resistant-tuberculosis-in-the-kharkiv-region%2C-ukraine. 2021-02-07 https://www.tbnet.eu/tbnet-publications/performance-of-immune-based-and-microbiological-tests-in-children-with-tuberculosis-meningitis-in-europe%3A-a-multicentre-paediatric-tuberculosis-network-european-trials-group-(ptbnet)-study.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/the-tuberculosis-network-european-trials-group-(tbnet)-ers-clinical-research-collaboration%3A-addressing-drug-resistant-tuberculosis-through-european-cooperation.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/burden-and-characteristics-of-the-comorbidity-tuberculosis-diabetes-in-europe%3A-tbnet-prevalence-survey-and-case-control-study. 2021-02-07 https://www.tbnet.eu/tbnet-publications/tuberculosis-disease-in-children-and-adolescents-on-therapy-with-anti-tumor-necrosis-factor-alpha-agents%3A-a-collaborative%2C-multi-centre-ptbnet-study.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/clofazimine-does-not-lead-to-significant-qt-interval-prolongation%3A-a-multicentre-study. 2021-02-07 https://www.tbnet.eu/tbnet-publications/use-of-xpert-mtb%2Frif-ultra-assays-among-paediatric-tuberculosis-experts-in-europe. 2021-02-07 https://www.tbnet.eu/tbnet-publications/treatment-outcome-definitions-in-nontuberculous-mycobacterial-pulmonary-disease%3A-an-ntm-net-consensus-statement. 2021-02-07 https://www.tbnet.eu/tbnet-publications/clinical-management-of-multidrug-resistant-tuberculosis-in-16-european-countries. 2021-02-07 https://www.tbnet.eu/tbnet-publications/qt-prolongation-and-cardiac-toxicity-of-new-tuberculosis-drugs-in-europe%3A-a-tuberculosis-network-european-trialsgroup-(tbnet)-study. 2021-02-07 https://www.tbnet.eu/tbnet-publications/tackling-the-mdr-tb-epidemic-in-ukraine%3A-every-little-helps-%E2%80%A6-and-much-more-needed. 2021-02-07 https://www.tbnet.eu/tbnet-publications/reply%3A-benefit-of-the-shorter-multidrug-resistant-tuberculosis-treatment-regimen-in-california-and-modified-eligibility-criteria.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/poor-adherence-to-management-guidelines-in-nontuberculous-mycobacterial-pulmonary-diseases. 2021-02-07 https://www.tbnet.eu/tbnet-publications/management-of-child-mdr-tb-contacts-across-countries-in-the-who-european-region%3A-a-survey-of-current-practice. 2021-02-07 https://www.tbnet.eu/tbnet-publications/treatment-outcomes-of-mdr-tb-and-hiv-co-infection-in-europe. 2021-02-07 https://www.tbnet.eu/tbnet-publications/mdr-tb-in-eastern-europe-in-the-era-of-the-tb-elimination-action-framework. 2021-02-07 https://www.tbnet.eu/tbnet-publications/tuberculosis-treatment-outcomes-in-europe%3A-based-on-treatment-completion%2C-not-cure.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/infection-control%2C-genetic-assessment-of-drug-resistance-and-drug-susceptibility-testing-in-the-current-management-of-multidrug%2Fextensively-resistant-tuberculosis-(m%2Fxdr-tb)-in-europe%3A-a-tuberculosis-network-european-trialsgroup-(tbnet)-study. 2021-02-07 https://www.tbnet.eu/tbnet-publications/the-tuberculosis-network-european-trials-group-(tbnet)%3A-new-directions-in-the-management-of-tuberculosis. 2021-02-07 https://www.tbnet.eu/tbnet-publications/european-shortage-of-purified-protein-derivative-and-its-impact-on-tuberculosis-screening-practices.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/viral-load-and-risk-of-tuberculosis-in-hiv-infection. 2021-02-07 https://www.tbnet.eu/tbnet-publications/more-on-treatment-outcomes-in-multidrug-resistant-tuberculosis. 2021-02-07 https://www.tbnet.eu/tbnet-publications/limited-benefit-of-the-new-shorter-multidrug-resistant-tuberculosis-regimen-in-europe.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/the-impact-of-bacille-calmette-gu%C3%A9rin-shortage-on-immunisation-practice-and-policies-in-europe---a-paediatric-tuberculosis-network-european-trials-group-(ptbnet)-survey. 2021-02-07 https://www.tbnet.eu/tbnet-publications/treatment-outcomes-in-multidrug-resistant-tuberculosis.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/clinical-implications-of-molecular-drug-resistance-testing-for-mycobacterium-tuberculosis%3A-a-tbnet%2Fresist-tb-consensus-statement. 2021-02-07 https://www.tbnet.eu/tbnet-publications/pregnancy-in-patients-with-tuberculosis%3A-a-tbnet-cross-sectional-survey. 2021-02-07 https://www.tbnet.eu/tbnet-publications/thermostability-of-ifn-%CE%B3-and-ip-10-release-assays-for-latent-infection-with-mycobacterium-tuberculosis%3A-a-tbnet-study.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/risk-assessment-of-tuberculosis-in-contacts-by-ifn-%CE%B3-release-assays.-a-tuberculosis-network-european-trials-group-study. 2021-02-07 https://www.tbnet.eu/tbnet-publications/numbers-needed-to-treat-to-prevent-tuberculosis. 2021-02-07 https://www.tbnet.eu/tbnet-publications/tuberculosis-in-young-refugees. 2021-02-07 https://www.tbnet.eu/tbnet-publications/multidrug-resistant-tuberculosis-in-europe%2C-2010-2011. 2021-02-07 https://www.tbnet.eu/tbnet-publications/availability%2C-price-and-affordability-of-anti-tuberculosis-drugs-in-europe%3A-a-tbnet-survey. 2021-02-07 https://www.tbnet.eu/tbnet-publications/beyond-multidrug-resistant-tuberculosis-in-europe%3A-a-tbnet-study.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/current-status-of-bacille-calmette-gu%C3%A9rin-(bcg)-immunisation-in-europe---a-ptbnet-survey-and-review-of-current-guidelines. 2021-02-07 https://www.tbnet.eu/tbnet-publications/false-negative-interferon-%CE%B3-release-assay-results-in-active-tuberculosis%3A-a-tbnet-study.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/availability-and-use-of-molecular-microbiological-and-immunological-tests-for-the-diagnosis-of-tuberculosis-in-europe.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/risk-assessment-of-tuberculosis-in-immunocompromised-patients.-a-tbnet-study. 2021-02-07 https://www.tbnet.eu/tbnet-publications/illness-perception-in-tuberculosis-by-implementation-of-the-brief-illness-perception-questionnaire---a-tbnet-study. 2021-02-07 https://www.tbnet.eu/tbnet-publications/management-of-patients-with-multidrug-resistant%2Fextensively-drug-resistant-tuberculosis-in-europe%3A-a-tbnet-consensus-statement.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/inclusion-of-latent-tuberculosis-infection-as-a-separate-entity-into-the-international-classification-of-diseases.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/the-geographic-diversity-of-nontuberculous-mycobacteria-isolated-from-pulmonary-samples%3A-an-ntm-net-collaborative-study. 2021-02-07 https://www.tbnet.eu/tbnet-publications/tbnet---collaborative-research-on-tuberculosis-in-europe. 2021-02-07 https://www.tbnet.eu/tbnet-publications/the-risk-of-tuberculosis-in-transplant-candidates-and-recipients%3A-a-tbnet-consensus-statement.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/identifying-predictors-of-interferon-%CE%B3-release-assay-results-in-pediatric-latent-tuberculosis%3A-a-protective-role-of-bacillus-calmette-guerin%3F%3A-a-ptb-net-collaborative-study. 2021-02-07 https://www.tbnet.eu/tbnet-publications/interferon-%CE%B3-release-assays-for-the-diagnosis-of-active-tuberculosis%3A-a-systematic-review-and-meta-analysis. 2021-02-07 https://www.tbnet.eu/tbnet-publications/a-multicentre-evaluation-of-the-accuracy-and-performance-of-ip-10-for-the-diagnosis-of-infection-with-m.-tuberculosis. 2021-02-07 https://www.tbnet.eu/tbnet-publications/interferon-%CE%B3-release-assays-for-the-diagnosis-of-latent-mycobacterium-tuberculosis-infection%3A-a-systematic-review-and-meta-analysis. 2021-02-07 https://www.tbnet.eu/tbnet-publications/development-of-a-standardised-tool-to-survey-mdr-%2Fxdr-tb-case-management-in-europe. 2021-02-07 https://www.tbnet.eu/tbnet-publications/the-risk-of-tuberculosis-related-to-tumour-necrosis-factor-antagonist-therapies%3A-a-tbnet-consensus-statement.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/tuberculosis-contact-investigation-in-low-prevalence-countries%3A-a-european-consensus.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/comparison-of-interferon-gamma-release-assays-and-tuberculin-skin-test-in-predicting-active-tuberculosis-(tb)-in-children-in-the-uk%3A-a-paediatric-tb-network-study. 2021-02-07 https://www.tbnet.eu/tbnet-publications/comment-on%3A-daily-300-mg-dose-of-linezolid-for-the-treatment-of-intractable-multidrug-resistant-and-extensively-drug-resistant-tuberculosis. 2021-02-07 https://www.tbnet.eu/tbnet-publications/epidemiology-and-clinical-management-of-xdr-tb%3A-a-systematic-review-by-tbnet.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/consensus-not-yet-reached-on-key-drugs-for-extensively-drug-resistant-tuberculosis-treatment.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/multidrug-resistant-and-extensively-drug-resistant-tuberculosis-in-the-west.-europe-and-united-states%3A-epidemiology%2C-surveillance%2C-and-control. 2021-02-07 https://www.tbnet.eu/tbnet-publications/mdr-tb-and-xdr-tb%3A-drug-resistance-and-treatment-outcomes. 2021-02-07 https://www.tbnet.eu/tbnet-publications/a-retrospective-tbnet-assessment-of-linezolid-safety%2C-tolerability-and-efficacy-in-multidrug-resistant-tuberculosis. 2021-02-07 https://www.tbnet.eu/tbnet-publications/ltbi%3A-latent-tuberculosis-infection-or-lasting-immune-responses-to-m.-tuberculosis%3F-a-tbnet-consensus-statement.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/bronchoalveolar-lavage-enzyme-linked-immunospot-for-a-rapid-diagnosis-of-tuberculosis%3A-a-tuberculosis-network-european-trialsgroup-study. 2021-02-07 https://www.tbnet.eu/tbnet-publications/evaluating-the-potential-of-ip-10-and-mcp-2-as-biomarkers-for-the-diagnosis-of-tuberculosis. 2021-02-07 https://www.tbnet.eu/tbnet-publications/extensively-drug-resistant-tuberculosis-is-worse-than-multidrug-resistant-tuberculosis%3A-different-methodology-and-settings%2C-same-results. 2021-02-07 https://www.tbnet.eu/tbnet-publications/fluoroquinolones%3A-are-they-essential-to-treat-multidrug-resistant-tuberculosis%3F 2021-02-07 https://www.tbnet.eu/tbnet-publications/resistance-to-second-line-injectables-and-treatment-outcomes-in-multidrug-resistant-and-extensively-drug-resistant-tuberculosis-cases. 2021-02-07 https://www.tbnet.eu/tbnet-publications/accuracy-of-immunodiagnostic-tests-for-active-tuberculosis-using-single-and-combined-results%3A-a-multicenter-tbnet-study.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/multidrug--and-extensively-drug-resistant-tuberculosis%2C-germany. 2021-02-07 https://www.tbnet.eu/tbnet-publications/extensively-drug-resistant-tuberculosis%2C-italy-and-germany.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/clinical-and-operational-value-of-the-extensively-drug-resistant-tuberculosis-definition.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/active-case-finding-of-tuberculosis-in-europe%3A-a-tuberculosis-network-european-trials-group-(tbnet)-survey.- 2021-02-07 https://www.tbnet.eu/tbnet-publications/use-of-a-t-cell-interferon-gamma-release-assay-for-the-diagnosis-of-tuberculous-pleurisy. 2021-02-07